Harmanen Minna, Hujo Mika, Sund Reijo, Sorigue Marc, Khan Madiha, Prusila Roosa, Klaavuniemi Tuula, Kari Esa, Jantunen Esa, Sunela Kaisa, Rajamäki Aino, Alanne Erika, Kuitunen Hanne, Sancho Juan-Manuel, Jukkola Arja, Rönkä Aino, Kuittinen Outi
Faculty of Health Sciences, School of Medicine, University of Eastern Finland, Kuopio, Finland.
Faculty of Science and Forestry, School of Computing, University of Eastern Finland, Kuopio, Finland.
Hematol Oncol. 2025 Jan;43(1):e70024. doi: 10.1002/hon.70024.
Mantle cell lymphoma is a rare type of B-cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development is hindered by the high costs of targeted therapies. To provide a baseline for future assessment of costs and benefits of new and emerging MCL treatments, we established a predictive simulated model of lifetime treatment trajectories based on a retrospective cohort of chemoimmunotherapy era patients diagnosed and treated between the year 2000 and 2020.
套细胞淋巴瘤是一种罕见的B细胞淋巴瘤，被认为无法治愈但可治疗。近年来，套细胞淋巴瘤的治疗选择成倍增加，治疗重点预计将从传统的化疗免疫疗法转向精准医学。然而，这种发展受到靶向治疗高昂成本的阻碍。为了为未来评估新兴套细胞淋巴瘤治疗的成本和效益提供一个基线，我们基于2000年至2020年期间诊断和治疗的化疗免疫疗法时代患者的回顾性队列，建立了一个终身治疗轨迹的预测模拟模型。
